Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Perioperative systemic therapy for bladder cancer.

Eulitt PJ, Bjurlin MA, Milowsky MI.

Curr Opin Urol. 2019 May;29(3):220-226. doi: 10.1097/MOU.0000000000000600.

PMID:
30855376
2.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE.

Cancer. 2019 Feb 15;125(4):533-540. doi: 10.1002/cncr.31817. Epub 2018 Dec 20.

PMID:
30570744
3.

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.

Rose TL, Chism DD, Alva AS, Deal AM, Maygarden SJ, Whang YE, Kardos J, Drier A, Basch E, Godley PA, Dunn MW, Kim WY, Milowsky MI.

Br J Cancer. 2018 Oct;119(7):801-807. doi: 10.1038/s41416-018-0229-0. Epub 2018 Oct 8.

PMID:
30293995
4.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
5.

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.

Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, Rathmell WK, Swanstrom R, Parker JS, Serody JS, Selitsky SR, Vincent BG.

J Clin Invest. 2018 Nov 1;128(11):4804-4820. doi: 10.1172/JCI121476. Epub 2018 Oct 2.

6.

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.

Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI.

JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168.

PMID:
29978216
7.

Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma.

Yin Q, Hung SC, Rathmell WK, Shen L, Wang L, Lin W, Fielding JR, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D.

Clin Radiol. 2018 Sep;73(9):782-791. doi: 10.1016/j.crad.2018.04.009. Epub 2018 May 23.

PMID:
29801658
8.

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.

Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, Herr HW, Huang WC, Taneja SS, Woods M, Ostrovnaya I, Al-Ahmadie H, Arcila ME, Riches JC, Meier A, Bourque C, Shady M, Won H, Rose TL, Kim WY, Kania BE, Boyd ME, Cipolla CK, Regazzi AM, Delbeau D, McCoy AS, Vargas HA, Berger MF, Solit DB, Rosenberg JE, Bajorin DF.

J Clin Oncol. 2018 Jul 1;36(19):1949-1956. doi: 10.1200/JCO.2017.75.0158. Epub 2018 May 9.

9.

Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.

Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G.

Oncotarget. 2018 Apr 13;9(28):19861-19873. doi: 10.18632/oncotarget.24888. eCollection 2018 Apr 13.

10.

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: ASCO Clinical Practice Guideline Summary.

Morris MJ, Rumble RB, Milowsky MI.

J Oncol Pract. 2018 May;14(5):319-322. doi: 10.1200/JOP.18.00075. Epub 2018 Apr 12. No abstract available.

PMID:
29648921
11.

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.

PMID:
29641297
12.

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI.

J Clin Oncol. 2018 May 20;36(15):1521-1539. doi: 10.1200/JCO.2018.78.0619. Epub 2018 Apr 2.

PMID:
29608397
13.

Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Lotan Y, Woldu SL, Sanli O, Black P, Milowsky MI.

BJU Int. 2018 Sep;122(3):434-440. doi: 10.1111/bju.14220. Epub 2018 Apr 24.

PMID:
29603871
14.

Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE.

J Immunother Cancer. 2017 Sep 28;5(1):80. doi: 10.1186/s40425-017-0280-z. No abstract available.

15.

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Acta Oncol. 2018 Apr;57(4):491-497. doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30.

PMID:
28853615
16.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.

J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23.

17.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.

Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE.

J Immunother Cancer. 2017 Aug 15;5(1):68. doi: 10.1186/s40425-017-0271-0. Erratum in: J Immunother Cancer. 2017 Sep 28;5(1):80.

18.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2019 Mar;5(2):242-249. doi: 10.1016/j.euf.2017.05.006. Epub 2017 Jun 3.

PMID:
28753897
19.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Eur Urol Focus. 2018 Dec;4(6):937-945. doi: 10.1016/j.euf.2017.03.011. Epub 2017 Mar 31.

PMID:
28753879
20.

A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.

Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI.

Oncologist. 2017 May;22(5):609-619. doi: 10.1634/theoncologist.2016-0319. Epub 2017 Apr 24. Review.

21.

Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.

Necchi A, Pond GR, Raggi D, Ottenhof SR, Djajadiningrat RS, Horenblas S, Khoo V, Hakenberg OW, Draeger D, Protzel C, Heidenreich A, Haidl F, Eigl BJ, Nappi L, Matsumoto K, Vaishampayan U, Woods ME, Salvioni R, Nicolai N, Catanzaro M, Giannatempo P, Geynisman DM, Preto M, Xylinas E, Milowsky MI, De Placido S, Di Lorenzo G, Sonpavde G.

Clin Genitourin Cancer. 2017 Oct;15(5):548-555.e3. doi: 10.1016/j.clgc.2017.02.002. Epub 2017 Feb 27.

PMID:
28325636
22.

Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study.

Yin Q, Hung SC, Wang L, Lin W, Fielding JR, Rathmell WK, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D.

Sci Rep. 2017 Mar 3;7:43356. doi: 10.1038/srep43356.

23.

Checkpoint inhibition: a new beginning for urothelial cancer.

Rose TL, Milowsky MI.

Lancet Oncol. 2017 Feb;18(2):160-161. doi: 10.1016/S1470-2045(16)30675-1. Epub 2017 Jan 10. No abstract available.

PMID:
28081913
24.

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.

Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, Perou CM, Soper JT, Whang YE, Yeh JJ, Martin G, Soper SA.

NPJ Precis Oncol. 2017;1. pii: 24. doi: 10.1038/s41698-017-0028-8. Epub 2017 Jul 25.

25.

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.

Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Bladder Cancer. 2016 Oct 27;2(4):405-413. doi: 10.3233/BLC-160072.

26.

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, Nanus DM, Scher HI.

Urol Oncol. 2016 Dec;34(12):530.e15-530.e21. doi: 10.1016/j.urolonc.2016.07.005. Epub 2016 Oct 17.

27.

Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.

Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1028-1036. doi: 10.1016/j.ijrobp.2016.08.023. Epub 2016 Aug 24.

PMID:
27727064
28.

Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators.

Eur Urol. 2017 Feb;71(2):281-289. doi: 10.1016/j.eururo.2016.09.042. Epub 2016 Oct 8.

29.

Claudin-low bladder tumors are immune infiltrated and actively immune suppressed.

Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, Iglesia MD, Milowsky MI, Parker JS, Kim WY, Vincent BG.

JCI Insight. 2016 Mar 17;1(3):e85902. doi: 10.1172/jci.insight.85902.

30.

The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors.

Miao L, Newby JM, Lin CM, Zhang L, Xu F, Kim WY, Forest MG, Lai SK, Milowsky MI, Wobker SE, Huang L.

ACS Nano. 2016 Oct 25;10(10):9243-9258. doi: 10.1021/acsnano.6b02776. Epub 2016 Sep 28.

31.

Reply to vitamin D status may explain racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era.

Rose TL, Milowsky MI.

Cancer. 2016 Dec 15;122(24):3893. doi: 10.1002/cncr.30343. Epub 2016 Sep 14. No abstract available.

32.

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma.

Abida W, Milowsky MI, Ostrovnaya I, Gerst SR, Rosenberg JE, Voss MH, Apolo AB, Regazzi AM, McCoy AS, Boyd ME, Bajorin DF.

Bladder Cancer. 2016 Jan 7;2(1):111-117.

33.

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.

Pham MN, Apolo AB, De Santis M, Galsky MD, Leibovich BC, Pisters LL, Siefker-Radtke AO, Sonpavde G, Steinberg GD, Sternberg CN, Tagawa ST, Weizer AZ, Woods ME, Milowsky MI.

World J Urol. 2017 Mar;35(3):367-378. doi: 10.1007/s00345-016-1885-4. Epub 2016 Jun 24. Review.

PMID:
27342991
34.

Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era.

Rose TL, Deal AM, Krishnan B, Nielsen ME, Smith AB, Kim WY, Milowsky MI.

Cancer. 2016 Oct;122(19):2988-95. doi: 10.1002/cncr.30146. Epub 2016 Jun 24.

35.

Creating a Culture of Safety Within an Institution: Walking the Walk.

Chera BS, Mazur L, Adams RD, Kim HJ, Milowsky MI, Marks LB.

J Oncol Pract. 2016 Oct;12(10):880-883. No abstract available.

PMID:
27328790
36.

Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.

Rose TL, Deal AM, Nielsen ME, Smith AB, Milowsky MI.

Cancer. 2016 Jul 1;122(13):2012-20. doi: 10.1002/cncr.30029. Epub 2016 May 25.

37.

Intrinsic Genomic Differences Between African American and White Patients With Clear Cell Renal Cell Carcinoma.

Krishnan B, Rose TL, Kardos J, Milowsky MI, Kim WY.

JAMA Oncol. 2016 May 1;2(5):664-667. doi: 10.1001/jamaoncol.2016.0005.

38.

Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, Boumansour P, Lee CT.

J Clin Oncol. 2016 Jun 1;34(16):1945-52. doi: 10.1200/JCO.2015.65.9797. Epub 2016 Mar 21.

PMID:
27001593
39.

Improving Systemic Chemotherapy for Bladder Cancer.

Rose TL, Milowsky MI.

Curr Oncol Rep. 2016 May;18(5):27. doi: 10.1007/s11912-016-0512-2. Review.

PMID:
26984414
40.

Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.

Brooks SA, Khandani AH, Fielding JR, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK.

Clin Cancer Res. 2016 Jun 15;22(12):2950-9. doi: 10.1158/1078-0432.CCR-15-2115. Epub 2016 Jan 19.

41.

Genomic profiling of advanced bladder cancer to guide the use of targeted therapeutics.

Green AK, Milowsky MI.

Cancer. 2016 Mar 1;122(5):676-7. doi: 10.1002/cncr.29825. Epub 2015 Dec 9. No abstract available.

42.

Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.

Falchook AD, Martin NE, Basak R, Smith AB, Milowsky MI, Chen RC.

Urol Oncol. 2016 Mar;34(3):119.e19-26. doi: 10.1016/j.urolonc.2015.09.014. Epub 2015 Oct 29.

PMID:
26526383
43.

Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome).

Vukina J, Chism DD, Sharpless JL, Raynor MC, Milowsky MI, Funkhouser WK.

Case Rep Pathol. 2015;2015:459318. doi: 10.1155/2015/459318. Epub 2015 Aug 16.

44.

A Small Step Toward Improving Systemic Treatment for Metastatic Bladder Cancer--At What Cost?

Rose TL, Milowsky MI.

Eur Urol. 2016 Apr;69(4):642-644. doi: 10.1016/j.eururo.2015.08.039. Epub 2015 Sep 4. No abstract available.

PMID:
26346677
45.

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.

Crona DJ, Milowsky MI, Whang YE.

Clin Pharmacol Ther. 2015 Dec;98(6):582-9. doi: 10.1002/cpt.256. Epub 2015 Oct 1. Review.

46.

Improving Patient Safety in Clinical Oncology: Applying Lessons From Normal Accident Theory.

Chera BS, Mazur L, Buchanan I, Kim HJ, Rockwell J, Milowsky MI, Marks LB.

JAMA Oncol. 2015 Oct;1(7):958-64. doi: 10.1001/jamaoncol.2015.0891. Erratum in: JAMA Oncol. 2015 Oct;1(7):989.

PMID:
26182183
47.

Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.

Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI.

Urol Oncol. 2015 Sep;33(9):386.e1-6. doi: 10.1016/j.urolonc.2015.05.028. Epub 2015 Jun 27.

48.

Management of muscle-invasive bladder cancer in the elderly.

Rose TL, Milowsky MI.

Curr Opin Urol. 2015 Sep;25(5):459-67. doi: 10.1097/MOU.0000000000000190. Review.

PMID:
26075567
49.

Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure.

Green AK, Corty RW, Wood WA, Meeneghan M, Reeder-Hayes KE, Basch E, Milowsky MI, Dusetzina SB.

Oncologist. 2015 May;20(5):516-22. doi: 10.1634/theoncologist.2014-0432. Epub 2015 Apr 17.

50.

Multidisciplinary care of the urothelial cancer patient.

Balar AV, Milowsky MI.

Urol Clin North Am. 2015 May;42(2):xiii. doi: 10.1016/j.ucl.2015.03.001. No abstract available.

PMID:
25882568

Supplemental Content

Loading ...
Support Center